Acumen Pharmaceuticals, Inc., today announced it has completed closing of a $500,000 financing led by NeuroVentures Fund, L.P. and BVF Partners L.P. (BVF). Acumen will use the proceeds to fund on-going preclinical development of ACU-193, a monoclonal antibody that selectively binds to and captures soluble oligomers of the amyloid-beta peptide.
ACU-193 Highlights and Development Timeline
- Selective, high affinity binding of soluble amyloid beta oligomers, which are now recognized widely as key pathogenic structures in Alzheimer’s disease;
- Targets the most scientifically validated Aβ toxin (soluble amyloid beta oligomers);
- Distinct from all other Aβ antibodies in development that either have selective affinity for non-toxic monomer or relatively non-toxic fibrillar Aβ;
- Expected to deliver acute and chronic benefits for Mild Cognitive Impairment (MCI) and mild to moderate Alzheimer patients;
- Multi-national pharmaceutical company quality IND-enabling data set (in vitro & in vivo efficacy, PK, safety, CMC);
- IND enabling studies and clinical trial design accepted by FDA in pre-IND meeting;
- Patent protection beyond 2030.
About Acumen Pharmaceuticals Inc.
Acumen is a world leader in experimental therapeutics that directly target the key molecular cause of Alzheimer’s disease. Acumen’s clinical candidate, ACU-193, is the first drug to selectively block soluble Aβ oligomers, small protein assemblies that trigger memory malfunction and cause nerve cell degeneration. ACU-193 is expected to reverse memory loss and stop Alzheimer degeneration by preventing soluble amyloid beta oligomers from attacking nerve cell synapses. Acumen’s experienced management team is currently working to complete IND-enabling studies that will propel ACU-193 into human clinical trials.
Acumen was founded based on the discovery of soluble Aβ oligomers and their memory compromising ability by founding scientists William Klein and Grant Krafft (Northwestern University) and Caleb Finch (U. Southern California).